MapLight Therapeutics, Inc.
MPLTDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
9dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
MPLT Earnings Report
EPS Est: $-1.40 | FQ end 2026-06
ML-007C-MA BID Phase 2 Est. Readout
Primary completion for ML-007C-MA BID trial (NCT07038876) in Schizophrenia
Failed to meet primary endpoint
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How MPLT's past catalysts played out
ML-007C-MA
Psychosis Associated With Alzheimer's Disease
ML-004 (IR)/(ER) tablet
Autism Spectrum Disorder
ML-007C-MA BID
Schizophrenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ML-007C-MA | Phase 2 | Psychosis Associated With Alzheimer's Disease | - | - |
ML-004 (IR)/(ER) tablet | Phase 2 | Autism Spectrum Disorder | - | - |
ML-007C-MA BID | Phase 2 | Schizophrenia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MapLight Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in MapLight Therapeutics, Inc.'s (MPLT) pipeline across Phase 2. Its lead program is ML-007C-MA (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MapLight Therapeutics, Inc.'s next FDA catalyst?→
MapLight Therapeutics, Inc.'s (MPLT) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MPLT biotech catalysts?→
Add MPLT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MapLight Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.